Literature DB >> 25163635

Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis.

Takeji Umemura1, Soichiro Shibata1, Tomohiro Sekiguchi1, Hiroyuki Kitabatake1, Yuichi Nozawa1, Sadahisa Okuhara1, Takefumi Kimura1, Susumu Morita1, Michiharu Komatsu1, Akihiro Matsumoto1, Eiji Tanaka1.   

Abstract

AIM: Although hyponatremia is associated with a poor prognosis in liver cirrhosis, little is known about the clinical significance of serum sodium concentration in cirrhosis in Japan. This study investigated associations of mortality in Japanese cirrhosis patients taking conventional diuretics with serum sodium concentration and other clinical characteristics.
METHODS: A total of 171 consecutive patients with cirrhosis who were taking diuretic medication were enrolled retrospectively. We determined the prevalence of low serum sodium concentration and searched for associations with age, sex, etiology, complications of cirrhosis, liver function tests and Model for End-Stage Liver Disease (MELD) and MELD-Na scores. The predictive ability of sodium level on mortality was also investigated.
RESULTS: Median serum sodium concentration was 139 mEq/L (interquartile range, 137-141). Only eight of 171 (4.7%) patients had low serum sodium (<130 mEq/L). Median MELD-Na score was 10.5 (interquartile range, 8.0-14.3). Cumulative survival rates were significantly lower in patients with Na of less than 139 mEq/L or MELD-Na score of 10.5 or more (log-rank test, P = 0.017 and P = 0.0002, respectively). Several liver function tests, MELD and MELD-Na scores, and the incidence of ascites were all significantly associated with patients having Na of less than 139 mEq/L.
CONCLUSION: Serum sodium concentration below 139 mEq/L and MELD-Na score above 10.5 may be predictive markers for mortality in patients with cirrhosis despite being within normal ranges. These markers may help to better assess and manage the prognosis of patients with cirrhosis in Japan.
© 2014 The Japan Society of Hepatology.

Entities:  

Keywords:  Liver cirrhosis; MELD-Na; mortality; sodium

Year:  2014        PMID: 25163635     DOI: 10.1111/hepr.12412

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

1.  Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.

Authors:  Takamasa Ohki; Koki Sato; Tomoharu Yamada; Mari Yamagami; Daisaku Ito; Koki Kawanishi; Kentaro Kojima; Michiharu Seki; Nobuo Toda; Kazumi Tagawa
Journal:  World J Hepatol       Date:  2015-06-28

2.  Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.

Authors:  Toshiyuki Tahara; Kiyoto Mori; Mari Mochizuki; Ryoko Ishiyama; Marin Noda; Hitomi Hoshi; Alan Kawarai Lefor; Satoshi Shinozaki
Journal:  Biomed Rep       Date:  2017-10-23

3.  Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.

Authors:  Ying-Fen Hong; Zhan-Hong Chen; Xiao-Kun Ma; Xing Li; Dong-Hao Wu; Jie Chen; Min Dong; Li Wei; Tian-Tian Wang; Dan-Yun Ruan; Ze-Xiao Lin; Jing-Yun Wen; Qu Lin; Chang-Chang Jia; Xiang-Yuan Wu
Journal:  Tumour Biol       Date:  2015-11-11

4.  Hyponatremia in hepatocellular carcinoma complicating with cirrhosis.

Authors:  Hiroki Nishikawa; Ryuichi Kita; Toru Kimura; Yoshiaki Ohara; Azusa Sakamoto; Sumio Saito; Norihiro Nishijima; Akihiro Nasu; Hideyuki Komekado; Yukio Osaki
Journal:  J Cancer       Date:  2015-04-01       Impact factor: 4.207

5.  The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.

Authors:  Tomomi Kogiso; Mutsuki Kobayashi; Kuniko Yamamoto; Yuichi Ikarashi; Kazuhisa Kodama; Makiko Taniai; Nobuyuki Torii; Etsuko Hashimoto; Katsutoshi Tokushige
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

6.  Effect of psoas muscle mass after endoscopic therapy for patients with esophageal varices.

Authors:  Hiroki Nishikawa; Yukihisa Yuri; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Ryo Takata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

7.  Renal impairment is associated with increased risk of mortality in patients with cirrhosis: A retrospective cohort study.

Authors:  Takeji Umemura; Satoru Joshita; Soichiro Shibata; Ayumi Sugiura; Tomoo Yamazaki; Naoyuki Fujimori; Akihiro Matsumoto; Eiji Tanaka
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

8.  Development and validation of a nomogram for predicting overall survival in cirrhotic patients with acute kidney injury.

Authors:  Yi-Peng Wan; An-Jiang Wang; Wang Zhang; Hang Zhang; Gen-Hua Peng; Xuan Zhu
Journal:  World J Gastroenterol       Date:  2022-08-14       Impact factor: 5.374

9.  Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.

Authors:  Shuzhen Wang; Xin Zhang; Tao Han; Wen Xie; Yonggang Li; Hong Ma; Roman Liebe; Honglei Weng; Hui-Guo Ding
Journal:  BMC Gastroenterol       Date:  2018-09-04       Impact factor: 3.067

10.  Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.

Authors:  Manabu Hayashi; Kazumichi Abe; Masashi Fujita; Ken Okai; Atsushi Takahashi; Hiromasa Ohira
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.